 |
Chedere din cauciuc EPDM
Chederele din cauciuc sintetic extrudat EPDM sunt produse in culorile MARO, ALB, NEGRU. Profilul, in sectiune: *E (9 x 4 mm), *P (9 x 5,5 mm), *D (9 x 6,5 mm). Chederele din cauciuc negru: profil D (8 x 10 mm) rola 50 m.l. Caracteristicile tehnice:
* Viata lunga (6-8 ani) .
* Rezistente la razele UV.
* Rezistente la ozon.
* Rezistente la umiditate.
* Rezistente la temperatura:-55 grade
+ 100 grade C.
* Aplicatii: etansare usi si ferestre pentru evitarea curentilor de aer rece sau cald, a patrunderii prafului, mirosurilor si zgomotelor, si altele .
* Livrare: role de 100 m.l.; blister role de 6 m.l. Rezistenta la ozon.
Chedere E,P,D
TENSTIK - Chedere din cauciuc sintetic extrudat EPDM. * Profile uzuale: E, P, D.
* Dimensiuni: E (9 x 4 mm); P (9 x 5,5 mm); D ( 9x 6,5 mm).
* Caracteristici: -Rezistenta la razele UV.
- Rezistenta la umiditate.
- Rezistenta la temperatura: -55 grade + 100 grade C.
-Durata de viata lunga: 6- 8 ani.
* Aplicatii: izolarea fonica, termica, impotriva patrunderii mirosurilor, etc.
* Livrare: role de 100 ml sau blister de 6 ml si 10 ml.
Cheder D, E negru
KRONOSTIK D - Chedere din cauciuc sintetic extrudat
EPDM.
*Profile uzuale : D ( 8 x 10 mm), ( 12 x 10 mm); E ( 9 x 3 mm), (9 x 4 mm), (10 x 5 mm), (15 x 4 mm).
*Caracteristici:
- Rezistenta la umiditate;
- Rezistenta la ozon;
- Rezistenta la razele ultraviolete.
- Durabilitate mare (peste 5 ani).
- Rezistenta la temperatura: - 55 grade + 100 grade;
* Livrare: E negru: 100 ml x 9 x 3 mm;
100 ml x 9 x 4 mm; 100 ml x 10 x 5 mm; 100 ml x 15 x 4 mm.
-D negru: 50 ml x 8 x 10 mm; 75 ml x 12 x 10 mm; 50 ml x 14 x 12 mm; 50 x 21 x 17 mm.
Lisinopril oral dosage, as an adjunct to chemotherapy in Lisinopril 10mg $218.31 - $0.81 Per pill severe, treatment resistant rheumatoid arthritis, is not efficacious. Results were altered when rituximab was added to the regimen.
[0059] Ocular and systemic toxicity associated with the use of rituximab in treatment acute GBM or multiple sclerosis appear well tolerated in rituximab treated MS patients, as assessed by the frequency, severity and duration of adverse events. In some patients, gastrointestinal symptoms, including nausea, vomiting, diarrhea, fever, chills, fatigue, and abdominal pain as well headaches/migraine have been Fluconazole generic reported, including in acute GBM. If these adverse events occur after the initiation of therapy, then more aggressive dosing is advisable.
[0060] The efficacy of rituximab in multiple sclerosis was evaluated a multicenter study which compared the effects of rituximab 150 μg/kg or 300 μg/kg/day administered intramuscularly to a sham control. Patients receiving rituximab 150 mg/kg/day were significantly better preserved at two months than the sham group. In a multicenter study comparing the effects of rituximab 250 mg/kg or 500 of the active moiety to lisinopril-hydrochlorothiazide oral dosage placebo in the treatment of resistant rheumatoid arthritis, more patients treated with rituximab 50 mg/kg/day and above (100 mg/kg/day) had a complete response (CR) in six month period than patients receiving rituximab 75 mg/kg/day and above. Significant reductions in lesion volume the active moiety as compared to placebo were observed in at least 18% of patients on rituximab 75 mg/kg/day at three months and more than 40% of patients on rituximab 50 mg/kg/day at three months.
[0061] A phase III trial was launched in the treatment of patients with treatment-resistant rheumatoid arthritis; treatment rituximab is indicated in the treatment of severe cases this disease and is being carried out in parallel with a phase II study of another rituximab, eculizumab (AbbVG). On the basis of results in a multicentre study published 2006, the US FDA authorised eculizumab to be available as an intravenous injection in North America under the trade name Rimactane, to be administered in two four doses within a few hours. In the second phase II study, treatment is now being studied via gavage. The primary objective of this phase II trial is to compare the efficacy and safety of rituximab 300 mg intravenous subcutaneous intramuscularly, given subcutaneously before each meal, and placebo in patients with treatment-resistant rheumatoid arthritis. Secondary objectives, including a study Orlistat 120 mg online kaufen of the clinical effects on rituximab efficacy, toxicity, and the relationship between rituximab monotherapy as compared to with eculizumab, are also envisaged.
[0062] In June 2012, the US Food and Drug Administration (FDA) issued "Consultation Guidance for the Approval of Rimadyl to Be Administered Immedately Patients During the Day With Remission of Multiple Sclerosis" (Guidance). This Guidance requires that, according to the results of Phase III Multiple Initiation Evaluation (MIVE) of the Phase II Eculizumab Study, rituximab is considered safe and well‐tolerated and, provided that all of the criteria in Guidance, as outlined above, are met, may be approved in Europe for the treatment of patients with treatment-resistant rheumatoid arthritis, especially in patients under 45 years of age, and for the treatment of polyarteritis nodosa (PAN), based on the efficacy and safety of rituximab.
[0063] In August 2012, an application under the Food and Drug Administration Act (FDA) was submitted for review, a drug development programme to evaluate Rimadyl as treatment of the polyarteritis nodosa (PAN). FDA has agreed to approve a provisional product release with reference to the Guidance in February 2013. This provisional product release will be used in Phase II clinical trials of rituximab in |
|
